Eyal Gottlieb

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT.

TargEDys SA develops microbiome-based solutions for appetite regulation. It provides humanity with easy means of regulating their eating behaviors for the third millennium. The company was founded by Pierre Dechelotte and Gregory Lambert 2011 and is headquartered in Paris, France.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.

Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York.

Metasight Diagnostics Ltd is an Israeli company that generates early diagnostic biomarkers. The company is based in Rehovot, Israel and was founded in 2020.

Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

Yonjin Venture LLC (Yonjin Venture) is a venture capital subsidiary of Yongjin Group, Inc. founded in 2018. The firm is headquartered in Cambridge, Massachusetts.

Ultivue, Inc. engages in provision of biotechnology services. It offers super-resolution imaging, single-molecule and diagnostics services. Its product Multiplex IHC Reagent Kits, a performance marker multiplexing detection and analysis.The company was founded by Peng Yin, David Walt and Ralf Jumgmann in 2015 and is headquartered in Cambridge, MA.

OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA.

DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

Kestrel Therapeutics, Inc. operates as a biotechnology development company. The company is based in Wayland, MA. The CEO of the company is Frank G. Haluska.

Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel.

INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam.

Accelmed Ventures provides pharmaceutical and biotech technology services. The company was founded by Mori Arkin in 2009 and is headquartered in Miami, Florida.

ACT Biotech, Inc. operates as a biopharmaceutical company which develops and commercializes targeted oral cancer drugs. The company was founded on February 15, 2008 and is headquartered in New York, NY.

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

Melanoma Therapeutics Foundation supports and researches treatments for melanoma. It provides resources for patients and physicians, supports investigators, and provides new drug development through bridging relationships between academia, pharmaceutical and biotechnology companies. The foundation is headquartered in San Francisco, California